Perlara Signs Rare Disease Pact with Novartis

October 20, 2016 | In a critical validation for a biotech firm espousing an unusual business model, Perlara has struck a deal to develop lysosomal storage disorder treatments with Novartis. The big pharma company will also make an undisclosed investment in the rare-disease-focused firm. Chemical & Engineering News